APIs and Excipients

Can Vaccine Development Be Safely Accelerated?

April 02, 2020

Biopharma companies responding to the COVID-19 outbreak think accelerating the development of vaccines is safe.

Comparison of Pharmaceutical Excipients and Food Ingredient Requirements

April 02, 2020

With ingredients sold to multiple markets, excipient manufacturers must understand the different regulatory requirements for pharma vs. food.

Considering Excipient Regulations

April 01, 2020

Understanding European GMPs and new rules from China for excipients are crucial for formulating solid-dosage drugs.

Suppliers Plan for Chloroquine Capacity

March 25, 2020

Bayer, Novartis, Mylan, Teva, report that they are working on supply.

USP Offers Support for COVID-19 Drug Developers

March 19, 2020

USP technical advisors will offer assistance to drug developers to ensure material quality and testing.

CEL-SCI Begins Development of Immunotherapy for COVID-19

March 09, 2020

The company is using its LEAPS peptide technology to develop the immunotherapy, which may be able to reduce COVID-19 viral load and tissue damage.

Innovations in CAR-T Therapies Across APAC Region Intensify Global Market Competition

March 05, 2020

Research from data and analytics company GlobalData shows that CAR-T cell therapy innovations across APAC will make the global market for these therapies more competitive.

Characterizing APIs is Essential for Combo Drug Formulations

March 02, 2020

Formulating fixed-dose combination drugs proves more complex than simply adding one ingredient to another.

Bovine Heparin Meets Acceptable Impurity Levels

February 17, 2020

An evaluation by USP indicates bovine heparin is a potential alternative to porcine heparin.

MilliporeSigma and ReForm Collaborate on Excipient Commercialization

February 13, 2020

The companies have entered into a global licensing and collaboration agreement to commercialize ReForm excipients used in biotherapeutic formulations.